

Table of Contents

Preface — V

List of contributing authors — VII

Table of Contents — XI

Introduction to Volume 2: Kallikrein-related Peptidases. Novel Cancer-related Biomarkers — 1

Bibliography — 2

1 Pathophysiology of Kallikrein-related Peptidases in Lung Cancer — 3

- 1.1 Introduction — 3
- 1.2 Expression pattern of KLKs in the normal lung — 3
- 1.3 KLKs in lung cancer — 6
- 1.4 Regulation of KLKs in the lung — 8
 - 1.4.1 Control of gene transcription — 8
 - 1.4.2 Post-translational control of KLK function — 10
- 1.5 Potential KLK targets in the lung — 11
 - 1.5.1 Substrates involved in host defense — 11
 - 1.5.2 Cytokines and growth factors — 13
 - 1.5.3 Pericellular and membrane-associated substrates — 16
- 1.6 Conclusion — 18
 - Acknowledgements — 19
 - Bibliography — 19

2 Clinical Relevance of Kallikrein-related Peptidases in Gastric and Colorectal Cancer — 27

- 2.1 Introduction — 27
- 2.2 Features of gastric and colorectal cancers — 27
- 2.3 Established biomarkers in gastric and colorectal cancer — 28
- 2.4 KLKs: novel biomarkers in gastric and colorectal cancer — 30
 - 2.4.1 Review of the clinical relevance of KLK expression in gastric cancer — 31
 - 2.4.2 Review of the clinical relevance of KLK expression in colorectal cancer — 35
- 2.5 Proteolytic activity of KLKs in gastric/colorectal cancers — 38
- 2.6 Effect of KLK expression on cell regulation and metabolic pathways — 39
- 2.7 Conclusion — 40
 - Bibliography — 40

3	Pathophysiology of Kallikrein-related Peptidases in Head and Neck Cancer — 45
3.1	Introduction — 45
3.2	A murine orthotopic xenograft model using urinary-type plasminogen activator receptor (uPAR) overexpressing OSCC cells mimics aggressive human OSCC — 47
3.3	Expression of KLKs in OSCC — 49
3.4	Potential functional role of KLK5 in regulating cell-cell junctional integrity in OSCC — 50
3.5	Conclusions and future directions — 54
	Acknowledgement — 55
	Bibliography — 55
4	PSA (Prostate-Specific Antigen) and other Kallikrein-related Peptidases in Prostate Cancer — 61
4.1	Introduction — 61
4.2	The role of KLKs in prostate cancer diagnosis, prognosis and monitoring — 61
4.2.1	PSA — 61
4.2.2	KLK2 — 65
4.2.3	Other KLKs — 65
4.2.4	Splicing and polymorphic variants — 66
4.3	Potential functional roles of KLKs in prostate cancer — 66
4.3.1	Sustaining proliferative signaling and evading growth suppressors — 67
4.3.2	Resisting cell death — 69
4.3.3	Inducing angiogenesis — 69
4.3.4	Activating invasion and metastasis — 71
4.3.5	Concerns about biological studies — 72
4.4	Conclusions and outlook — 72
	Bibliography — 73
5	Cellular Model Systems to Study the Tumor Biological Role of Kallikrein-related Peptidases in Ovarian and Prostate Cancer — 83
5.1	Introduction — 83
5.2	Development of cellular model systems in cancer research — 83
5.3	Traditional 3D cellular models commonly used in both ovarian and prostate cancers — 84
5.3.1	Soft agar colony assay — 84
5.3.2	3D-Matrigel™ — 85
5.4	Novel 3D cellular models in ovarian cancer biology — 86
5.4.1	Ovarian cancer — 86

5.4.2	3D-suspension model to mimic ascites suspension — 86
5.4.3	In vitro models for ovarian cancer invasion into the peritoneal membrane — 90
5.4.4	The role of 3D-collagen I matrix in ovarian cancer cell behavior — 92
5.4.5	A 3D-organotypic model to mimic ovarian cancer metastasis — 92
5.4.6	Bioengineered 3D culture systems for ovarian cancer — 93
5.5	Cellular models in prostate cancer — 95
5.5.1	Prostate cancer — 95
5.5.2	3D-suspension models for prostate cancer growth and metastasis — 97
5.5.3	<i>In vitro</i> models for prostate cancer angiogenesis — 98
5.5.4	Bioengineered 3D culture systems for prostate cancer growth and metastasis — 98
5.6	Challenges and future direction — 102
	Acknowledgment — 102
	Bibliography — 103
6	Clinical Relevance of Kallikrein-related Peptidases in Breast Cancer — 111
6.1	Introduction — 111
6.2	Expression of KLKs in normal breast tissue — 113
6.3	Clinical relevance of KLKs in breast cancer — 113
6.4	Hormonal regulation of KLKs in breast cancer — 127
6.5	Tumor suppressor role of KLKs in breast cancer — 129
6.6	DNA-methylation of KLKs as the basis of KLK downregulation in breast cancer — 130
6.7	Conclusions — 132
	Bibliography 132
7	Clinical Relevance of Kallikrein-related Peptidases in Ovarian Cancer — 145
7.1	Introduction — 145
7.2	Ovarian cancer pathology, diagnosis, and therapy — 145
7.3	KLKs in ovarian cancer — 147
7.3.1	Circulating KLKs as screening/diagnostic and/or prognostic ovarian cancer biomarkers — 148
7.3.2	Serum ovarian cancer biomarkers CA125 and KLKs — 155
7.3.3	Tumor tissue-associated KLKs as prognostic ovarian cancer biomarkers — 156
7.4	Tumor tissue-associated and blood-borne KLKs as predictive ovarian cancer biomarkers — 157
7.5	Conclusion — 158

Abbreviations — 159

Bibliography — 160

8 microRNAs: A New Control Mechanism for Kallikrein-related Peptidases in Kidney and Other Cancers — 167

8.1 Introduction — 167

8.1.1 KLK expression in normal kidney tissue — 167

8.1.2 KLK dysregulation in kidney cancer — 168

8.2 microRNAs (miRNA) — 169

8.2.1 Biogenesis — 169

8.2.2 miRNAs and cancer — 170

8.2.3 miRNA dysregulation in renal cell carcinoma — 170

8.2.4 The miRNA-KLK interaction — 171

8.3 miRNA control of KLK expression in renal cell carcinoma — 174

8.4 miRNA control of KLK expression in other cancers — 175

8.5 Conclusions and outlook — 176

Bibliography — 177

9 Genomic Instability of the *KLK*-locus in Cancer — 183

9.1 Introduction — 183

9.2 Defining genomic instability — 183

9.2.1 Defining CIN and its underlying mechanisms — 184

9.2.2 Methods for detecting CIN — 185

9.3 Chromosome 19 and the *KLK* locus in cancer — 186

9.3.1 Chromosome 19 — 186

9.3.2 The *KLK* locus and cancer — 187

9.3.3 *KLK* sequence mutations and single nucleotide polymorphisms in cancer — 188

9.3.4 *KLK* translocations — 189

9.3.5 Copy-number changes of the *KLK* locus — 191

9.4 Closing remarks — 193

Bibliography — 194

10 Kallikrein-related Peptidases as Biomarkers in Personalized Cancer Medicine — 201

10.1 Introduction — 201

10.2 The role of KLKs as cancer biomarkers for predicting and monitoring response to chemotherapy or endocrine therapy — 204

10.2.1 Prostate cancer — 206

10.2.2 Breast cancer — 207

10.2.3 Ovarian cancer — 207

10.3	Modulation of expression levels of <i>KLK</i> genes upon chemotherapy administration <i>in vitro</i> — 209
10.3.1	Prostate cancer cells — 210
10.3.2	Gastric cancer cells — 210
10.3.3	Breast cancer cells — 211
10.3.4	The role of microRNAs (miRNAs) that target <i>KLK</i> expression and the methylation status of <i>KLK</i> genes in the <i>in vitro</i> response of cancer cells to chemotherapy — 212
10.4	Conclusions and future directions — 213
	Bibliography — 214

	Index — 219
--	-------------